clinical trial · NCT07697560
Safety, Tolerability, and PK of AH-008 Following Single Ascending Dose in Healthy Subjects
AnHorn Medicines Co. Ltd.·phase1·recruiting·n = 32
Chemotherapy-induced Peripheral Neuropathy (CIPN)AH-008 for Injection, 150 mgAH-008 for Injection, Placebo
brief summary
This is a Phase 1, first-in-human (FIH), randomized, double-blind, placebo-controlled, parallel-group, single ascending dose (SAD) study to evaluate the safety, tolerability, and pharmacokinetics of AH-008 administered as a single intravenous infusion in healthy adult subjects. Four sequential dose cohorts will be evaluated, each with sentinel dosing and SRC-reviewed dose escalation.
started
Jun 10, 2026
primary completion
Sep 1, 2026
completion
Sep 1, 2026
last updated
Jul 13, 2026
official title
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Dose Escalation Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of AH-008 Following Single Ascending Dose Administration in Healthy Subjects
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol